14-day Premium Trial Subscription Sign Up For FreeGet Free
Nasdaq - Total Crash or Bounce-Up? Click To Watch.

$32.49 (-2.05%)

Volume: 2.301M

Closed: Sep 30, 2022

Hollow Logo Score: -3.615

EXACT Sciences Corporation Stock Forecast

$32.49 (-2.05%)

Volume: 2.301M

Closed: Sep 30, 2022

Score Hollow Logo -3.615

EXACT Sciences Corporation Company Profile

5505 Endeavor Lane

Madison WI 53719

608 284 5700

www.exactsciences.com

EXACT Sciences Corporation

Description

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

Hot Stocks To Watch:

IMPROVE YOUR TRADING GAME WITH A GOLDEN STAR

From 26 676 stocks, only a few dozen will trigger such a signal!

About EXACT Sciences Corporation

EXACT Sciences Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid th... EXAS Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT